BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, July 19, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Incyte to acquire Villaris and lead asset auremolimab for vitiligo
To read the full story,
subscribe
or
sign in
.
Dermatologic
Incyte to acquire Villaris and lead asset auremolimab for vitiligo
Oct. 4, 2022
Incyte Corp. has entered into an agreement to acquire Villaris Therapeutics Inc., a company developing antibody therapeutics for vitiligo.
BioWorld Science
Acquisition
Dermatologic
Monoclonal antibody
